Biomarkers predictive for clinical efficacy of anti-interleukin-4/13 receptor monoclonal antibody in patients with asthma

Biomarkers predictive for clinical efficacy of anti-interleukin-4/13 receptor monoclonal antibody in patients with asthma - Biomarkers for anti-interleukin-4/13 receptor alpha monoclonal antibody

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036302

Enrollment

Registered

2019-03-27

Start date

2019-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Subject is diagnosed with asthma according to the Japanese Asthma Prevention and Management Guidelines (JGL). -Participant demonstrates understanding and has provided an appropriately signed and dated informed consent

Exclusion criteria

Exclusion criteria: Exclusion criteria included COPD, interstitial pneumonia, infectious disease, and active cancer.

Design outcomes

Primary

Measure	Time frame
Biomarker discovery for clinical efficacy of anti-IL-4/13 receptor monoclonal antibody	—

Countries

Japan

Contacts

Public ContactNorihiro Harada

Juntendo University school of medicine Department of respiratory medicine

nor@juntendo.ac.jp03-3813-3111

Outcome results